Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals, Inc. (ARMP) Current Deferred Revenue (2016 - 2017)

Armata Pharmaceuticals' Current Deferred Revenue history spans 5 years, with the latest figure at $20000.0 for Q3 2017.

  • For Q3 2017, Current Deferred Revenue rose 11.11% year-over-year to $20000.0; the TTM value through Sep 2017 reached $20000.0, up 11.11%, while the annual FY2014 figure was $244000.0, 0.0% changed from the prior year.
  • Current Deferred Revenue for Q3 2017 was $20000.0 at Armata Pharmaceuticals, down from $58000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $350000.0 in Q2 2015 and bottomed at $18000.0 in Q3 2016.
  • The 5-year median for Current Deferred Revenue is $142000.0 (2015), against an average of $166357.1.
  • The largest annual shift saw Current Deferred Revenue plummeted 92.71% in 2016 before it skyrocketed 34.88% in 2017.
  • A 5-year view of Current Deferred Revenue shows it stood at $244000.0 in 2013, then changed by 0.0% to $244000.0 in 2014, then grew by 1.23% to $247000.0 in 2015, then tumbled by 92.71% to $18000.0 in 2016, then increased by 11.11% to $20000.0 in 2017.
  • Per Business Quant, the three most recent readings for ARMP's Current Deferred Revenue are $20000.0 (Q3 2017), $58000.0 (Q2 2017), and $86000.0 (Q1 2017).